MedTrace Logo

Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease

NCT07625384 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2026-06-04

No results posted yet for this study

Summary

The primary objective of the study is to evaluate the efficacy and safety of goflikicept (GFC) and olokizumab (OKZ) in patients with Still's disease

Conditions

  • Still Disease

Interventions

DRUG

Placebo

0.9% Sodium Chloride solution for Injection

BIOLOGICAL

Goflikicept

solution for subcutaneous injection and intravenous infusion, 40 mg/mL

BIOLOGICAL

Olokizumab

solution for subcutaneous injection and intravenous infusion, 160 mg/mL

Sponsors & Collaborators

  • R-Pharm International, LLC

    lead INDUSTRY

Principal Investigators

  • Mikhail Samsonov · R-Pharm International, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-18
Primary Completion
2027-12-14
Completion
2028-07-01

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07625384 on ClinicalTrials.gov